Shire Plc.’s (Shire) 3Q 08 revenues were supported by strong demand for high margin Specialty Pharmaceuticals and Human Genetic Therapies (HGT) products, in line with our expectations. However, margins exceeded our expectations, primarily due to lower-than-expected Research and Development (R&D) costs. The increasing demand and wider acceptance of Vyvanse and Elaprase should continue to support revenues in FY 2008 and FY 2009. Furthermore, Shire plans to launch Firazyr for the treatment of He

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Shire PLC (Nasdaq: SHPGY), O'Reilly Automotive, Inc. (Nasdaq: ORLY), Burlington Northern Santa Fe Corp. (NYSE: BNI), United Therapeutics Corp. (Nasdaq: UTHR) ...